



Antibody Response of Vaccines to SARS-CoV-2

Guest Editor:

Dr. Drishya Kurup

Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA

Deadline for manuscript submissions:

closed (1 May 2023)

Message from the Guest Editor

Dear Colleagues,

The COVID-19 pandemic has highlighted health and socioeconomic inequalities around the world. Several COVID-19 vaccines have been approved for human use worldwide. The past two years of the pandemic have allowed researchers a better understanding of SARS-CoV-2 and the antibody responses elicited by vaccines and natural infection. All currently approved vaccines utilize the SARS-CoV-2 spike protein and elicit IgG responses. Therefore, this Special Issue, “Antibody Response of Vaccines to SARS-CoV-2”, of Vaccines aims to present the latest findings to improve antibody responses, the type of antibody responses required for long-term protection, and future perspectives on new vaccine strategies and targets.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

- immunogenicity and efficacy of licensed vaccines
- New generations of vaccines against COVID-19
- Vaccination strategies for particular populations
- Antibody isotypes and their locations as well as roles in protection
- Immunological correlate of protection

I look forward to receiving your contributions.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)